Alex Thompson
Stock Analyst at Stifel
(2.85)
# 1,826
Out of 5,067 analysts
38
Total ratings
56.67%
Success rate
5.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Buy | $55 → $80 | $41.95 | +90.70% | 1 | Oct 29, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $43.68 | +48.81% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $35.79 | -30.15% | 4 | Sep 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $209.03 | +21.51% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $12.93 | +70.15% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $65.59 | -16.15% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $18.00 | +100.00% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $43.84 | +36.86% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $29.87 | +64.04% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $907.42 | -44.90% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $26.97 | +100.22% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $9.95 | -79.90% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $13.15 | +424.71% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $2.75 | -63.64% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $32.03 | +24.88% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $29.07 | +1,000.79% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $23.32 | +45.80% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.57 | +2,001.91% | 1 | Dec 14, 2022 |
AnaptysBio
Oct 29, 2025
Maintains: Buy
Price Target: $55 → $80
Current: $41.95
Upside: +90.70%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $43.68
Upside: +48.81%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $35.79
Upside: -30.15%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $209.03
Upside: +21.51%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $12.93
Upside: +70.15%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $65.59
Upside: -16.15%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $18.00
Upside: +100.00%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $43.84
Upside: +36.86%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $29.87
Upside: +64.04%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $907.42
Upside: -44.90%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $26.97
Upside: +100.22%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $9.95
Upside: -79.90%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $13.15
Upside: +424.71%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $2.75
Upside: -63.64%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $32.03
Upside: +24.88%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $29.07
Upside: +1,000.79%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $23.32
Upside: +45.80%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.57
Upside: +2,001.91%